Charts

The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.

ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good morning, and welcome to ImmunoGen’s Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call. Today’s conference is being recorded. At this time, I’d like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead. […]

Q4 2022 ImmunoGen Inc Earnings Call

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ImmunoGen, Inc. (IMGN), where a total of 19,624 contracts have traded so far, representing approximately 2.0 million underlying shares..

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Inc(NASDAQ: IMGN) announced a global, multi-targetlicense and option agreementthat grantedVertex ...

ImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue ...

ImmunoGen Reports Recent Progress and 2022 Financial Results

ImmunoGen Announces Global, Multi-Target Agreement with Vertex for Use of ImmunoGen's ADC Tech for Development of Novel Targeted Conditioning Agents

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ClearBridge Investments, an investment management firm, released its fourth-quarter 2022 “ClearBridge Multi Cap Growth Strategy” investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy outperformed the Russell 3000 Growth Index benchmark. The Strategy gained in six of the seven sectors on an absolute basis in which it was […]

Every investor in ImmunoGen, Inc. ( NASDAQ:IMGN ) should be aware of the most powerful shareholder groups. With 72...

ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Helen of Troy Ltd. (HELE), where a total volume of 2,892 contracts has been traded thus far today, a contract volume which is representative of approximately 289,200 underlying shares (given that every 1 contract represents 100 underlying shares)..

ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Today is shaping up negative for ImmunoGen, Inc. ( NASDAQ:IMGN ) shareholders, with the analysts delivering a...

In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in ...

Over the past 3 months, 6 analysts have published their opinion on Immunogen (NASDAQ:IMGN) stock. These analysts are typically employed ...

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat ...

Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7.Citigroup analyst Yigal Nochomovitz maintained a ...

Companies in The News Are: IMGN, TGTX, TSLA, MSFT

ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed

The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which includeImmunoGen ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 3:45pm PT (6:45pm ET) on January 10, 2023.

Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will also bring Acotec’s products to western markets.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

In trading on Monday, shares of ImmunoGen, Inc. (IMGN) crossed below their 200 day moving average of $5.03, changing hands as low as $4.92 per share..

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (pivekimab) in combination with Vidaza® (azacitidine) and Venclexta® (venetoclax) in patients with relapsed/refractory (R/R) and frontline acute myeloid leukemia (AML). These findings were presented in an oral session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana.

ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in R/R Acute Myeloid Leukemia

Food and Drug Administration decisions andadvisory committee verdicts slated for Novemberwere mostly positive. New molecular ...

Immunogen (NASDAQ:IMGN) brought in sales totaling $15.38 million during Q3 according to data provided by Benzinga Pro. However, earnings ...

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would ...

Investors in ImmunoGen, Inc. (IMGN) saw new options begin trading this week, for the July 2023 expiration..

ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer

Program leverages NeoGenomics' expertise to provide ovarian cancer patients critical insights to ensure they are getting the right treatment

Tuesday, theFDA granted accelerated approvalforImmunoGen Inc's(NASDAQ: IMGN) Elahere (mirvetuximab ...

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat ...

Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. Tenax Therapeutics, Inc. ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Brunswick Corp. (BC), where a total of 3,218 contracts have traded so far, representing approximately 321,800 underlying shares..

U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in ...

Chardan Capital raised PDS Biotechnology Corporation (NASDAQ: PDSB) price target from $15 to $16. . Chardan Capital analyst Geulah ...

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading ...

TheFDA granted accelerated approvalforImmunoGen Inc's(NASDAQ: IMGN) Elahere (mirvetuximab ...

ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, November 4, 2022 at 06:30 AM. Here's what investors need to ...

ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results

Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of ...

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know ...

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or ...